An immunohistochemical study of chromogranin A and human epidermal growth factor-2 expression using initial prostate biopsy specimens from patients with bone metastatic prostate cancer

BJU International

Volumn 99, Issue 1, 2007, Pages 189-195

  Yamada, Yoshiaki ^a   Nakamura, Kogenta ^a   Aoki, Shigeyuki ^a   Taki, Tomohiro ^a   Naruse, Katsuya ^a   Matsubara, Hiroyuki ^a   Tobiume, Motoi ^a   Zennami, Kenji ^a   Katsuda, Remi ^a   Honda, Nobuaki ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone metastatic; Chromogranin A; HER 2; Immunohistochemistry; Neuroendocrine differentiation; Prognosis; Prostate cancer

Indexed keywords

ANTIANDROGEN; CHROMOGRANIN A; GAMMA UROGASTRONE; HUMAN EPIDERMAL GROWTH FACTOR 2; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEUROSECRETORY CELL; ORCHIECTOMY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION; STAINING;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BONE NEOPLASMS; CHROMOGRANIN A; EPIDERMAL GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2;

EID: 33845509926     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06500.x     Document Type: Article

References (31)

1. Abrahamsson PA. Neuroendocrine differentiation in prostate carcinoma. Prostate 1999; 39: 135-48
2. Bonkhoff H. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate Suppl 1998; 8: 18-22
3. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992; 70 (Suppl. 1): 254-68
4. di Sant'Agnese PA, Cockett AT. The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research. J Urol 1994; 152: 1927-31
5. McWilliam LJ, Manson C, George NJ. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. Br J Urol 1997; 80: 287-90
6. Krijnen JL, Bogdanowicz JF, Seldenrijk CA, Mulder PG, van der Kwast TH. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997; 158: 171-4
7. Ischia R, Hobisch A, Bauer R et al. Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate. J Urol 2000; 163: 1161-5
8. Berruti A, Dogliotti L, Mosca A et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000; 88: 2590-7
9. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H. Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002; 167: 512-5
10. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 1987; 235: 177-82
11. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244: 707-12
12. Press MF, Bernstein L, Thomas PA et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15: 2894-904
13. Iwamura M, Abrahamsson PA, Foss KA, Wu G, Cockett AT, Deftos LJ. Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 1994; 43: 675-9
14. Iwamura M, di Sant'Agnese PA, Wu G, Benning CM, Cockett AT, Gershagen S. Overexpression of human epidermal growth factor receptor and c-erbB-2 by neuroendocrine cells in normal prostatic tissue. Urology 1994; 43: 838-43
15. Ellis IO, Bartlett J, Dowsett M et al. Best Practice No 176: Update recommendations for HER2 testing in the UK. J Clin Pathol 2004; 57: 233-7
16. Soloway MS, Hardeman SW, Hickey D et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202
17. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992; 23: 273-9
18. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumors, 5th edn. New York: Wiley-Liss Inc, 1997
19. Carter P, Presta L, Gorman CM et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-9
20. Aprikian AG, Han K, Guy L, Landry F, Begin LR, Chevalier S. Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer. Prostate Suppl 1998; 8: 52-61
21. Casella R, Bubendorf L, Sauter G, Moch H, Mihatsch MJ, Gasser TC. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. J Urol 1998; 160: 406-10
22. Pruneri G, Galli S, Rossi RS et al. Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. Prostate 1998; 34: 113-20
23. Bostwick DG, Qian J, Pacelli A et al. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. J Urol 2002; 168: 1204-11
24. Aprikian AG, Cordon-Cardo C, Fair WR et al. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J Urol 1994; 151: 914-9
25. Jongsma J, Oomen MH, Noordzij MA et al. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res 2000; 60: 741-8
26. Nagakawa O, Fujiuchi Y, Fuse H, Saiki I. Differential effect of chromogranin A fragments on invasion and growth of prostate cancer cells in vitro. Urology 2003; 62: 553-8
27. Ross JS, Sheehan CE, Hayner-Buchan AM et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997; 79: 2162-70
28. Signoretti S, Montironi R, Manola J et al. HER-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000; 92: 1918-25
29. Koeppen HK, Wright BD, Burt AD et al. Overexpression of HER2/neu in solid tumors: an immunohistochemical survey. Histopathology 2001; 38: 96-104
30. Lara PN Jr, Chee KG, Longmate J et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium screening and phase II trial. Cancer 2004; 100: 2125-31
31. Morote J, de Torres I, Caceres C, Vallejo C, Schwartz S Jr, Reventos J. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer. Int J Cancer 1999; 84: 421-5